Quick answer: Eloralintide (development code LY3841136) is an investigational, once-weekly, selective amylin receptor agonist peptide developed by Eli Lilly and Company. It is in clinical development, with Phase 2 results published and Phase 3 studies registered. It differs from cagrilintide, which is described as a non-selective amylin and calcitonin receptor agonist from Novo Nordisk, and from pramlintide, the older approved amylin analogue. Eloralintide is not approved anywhere on the basis of the sources reviewed here, and V8 Peptides does not sell it. Its exact sequence and molecular weight are not publicly confirmed in the sources we opened.
Where the name eloralintide comes from, and other names
Eloralintide is the nonproprietary name used in the published literature and on ClinicalTrials.gov. Its development code is LY3841136, and trial records use the two names for the same compound. In some registered studies the compound is paired with tirzepatide and abbreviated “EloraTZP” in the study title. Online you will also see “elora,” which is informal shorthand rather than an official name.
Why does this matter to a lab buyer? When a compound is this new, searching by several names is the only way to find the primary records. Searching the full name and the LY code together is more reliable than relying on a nickname, and it keeps you anchored to documents written by the developer and by independent reviewers rather than to retail descriptions.
What an amylin receptor agonist is, in plain terms
Amylin is a peptide hormone that is co-secreted with insulin from pancreatic beta-cells. According to a 2026 narrative review, amylin slows gastric emptying, suppresses glucagon secretion and acts through central mechanisms involved in ending a meal. An amylin receptor agonist is a molecule designed to activate the same receptors that natural amylin activates.
The receptor side is a little unusual. Amylin receptors are not a single protein. They are complexes that include the calcitonin receptor (CTR), and the literature uses names such as amylin 1 receptor (AMY1R) and amylin 3 receptor (AMY3R) for the different complexes. Calcitonin itself also acts on the calcitonin receptor. That overlap is the reason “selectivity” is a recurring word in this field: a compound can be a broad agonist across amylin and calcitonin receptors, or it can be characterised as favouring particular amylin receptor subtypes.
Natural amylin has a tendency to aggregate, which makes it awkward as a laboratory or pharmaceutical starting point. A 2026 review notes that pramlintide was based on the structure of non-aggregating rat amylin, and that newer long-acting analogues were designed with improved understanding of amylin structure and receptor complexes. For a broader background on related receptor biology, see incretin receptors explained, which covers the neighbouring GLP-1 family.
What has been published so far
Everything below is investigational clinical research reported by the developer and by independent reviewers. It is described here as a record of what was studied and measured, not as guidance for any use.
Discovery and early characterisation. A 2025 paper in Molecular Metabolism describes eloralintide from discovery to clinical proof of concept. In cell assays, the compound preferentially activated the human AMY1R, with reported activation about 12-fold over CTR and 11-fold over AMY3R. In rats, both AMY1R and AMY3R were activated more potently than CTR. The same paper reports that, in lean rats, eloralintide produced significantly less conditioned taste avoidance than cagrilintide, which the authors describe as a non-selective amylin receptor agonist. It also reports pharmacokinetic work in rats and monkeys and a single-ascending-dose Phase 1 study in 48 healthy participants (NCT05295940).
Multiple-ascending-dose Phase 1. A 2026 paper in Diabetes, Obesity and Metabolism reports a 12-week, randomised, placebo-controlled, blinded study in 100 participants with obesity or overweight at three US centres. Its stated outcomes were safety, tolerability, pharmacokinetics and pharmacodynamics, including percent change in body weight. The authors describe exposure as dose proportional.
Phase 2. A paper in The Lancet reports a 48-week, double-blind, randomised, placebo-controlled Phase 2 study (NCT06230523) in 263 adults without type 2 diabetes at 46 US research centres. The primary endpoint was percent change in body weight from baseline at week 48. The study compared several fixed and escalating regimens against placebo, and the paper reports dose-dependent differences in body weight versus placebo, with nausea and fatigue named as the most common adverse events. The study was funded by Eli Lilly. The developer announced the topline results in a press release on 6 November 2025, describing eloralintide as an investigational once-weekly selective amylin receptor agonist.
Phase 3 and combination studies. ClinicalTrials.gov lists Eli Lilly and Company as lead sponsor of a number of eloralintide records. These include Phase 3 studies in adults with obesity or overweight with and without type 2 diabetes (for example NCT07321886 and NCT07282600), Phase 3 combination studies with tirzepatide (NCT07881458 and NCT07881432), and Phase 2 work with macupatide (NCT07215559). Smaller Phase 1 records examine special populations, such as people with renal impairment or reduced liver function. Recruitment statuses shift often, so read the registry entries for the current picture instead of relying on this summary.
Independent reviews. Several 2026 reviews place eloralintide among a group of long-acting amylin-based candidates that also includes cagrilintide, petrelintide and others. Reviews are secondary sources, so the primary papers listed in the references are the better place to check any figure.
Eloralintide vs cagrilintide vs pramlintide
The three compounds are often confused because all are amylin-pathway peptides. The table keeps to what the sources opened for this article support.
| Feature | Eloralintide | Cagrilintide | Pramlintide |
|---|---|---|---|
| Class | Amylin receptor agonist | Amylin receptor agonist | Amylin analogue |
| Reported selectivity | Described as selective; preferentially activated human AMY1R in cell assays | Described as a dual amylin receptor and calcitonin receptor agonist, or non-selective | Based on rat amylin; receptor profile not examined in the sources opened |
| Developer or sponsor | Eli Lilly and Company | Novo Nordisk (lead sponsor of its registered trials) | Not confirmed in the sources opened |
| Development stage | Investigational; Phase 2 published, Phase 3 registered | In clinical development, including a co-formulation with semaglutide (CagriSema) | Described as the first approved amylin analogue |
| Interval noted in literature | Once weekly | Long-acting | Described as needing frequent administration |
| Status as a research material | Brand-new name; no public sequence or reference standard confirmed; not sold by V8 Peptides | Longer research history | Long-established compound |
For a deeper look at the two older molecules, read cagrilintide vs pramlintide and the cagrilintide research overview. If you are comparing cagrilintide with other pathway peptides, the four-compound comparison sets out the differences by class.
What is not publicly confirmed
The sources we opened do not state eloralintide’s amino-acid sequence, its molecular weight, or its chemical modifications. A reader will find numbers for these in some online posts. Without a citation to a primary document, regard them as unconfirmed. The same goes for claims about how it is manufactured, its stability profile as a powder, or any comparison of structure with cagrilintide. We have left all of those out on purpose.
Eloralintide is an investigational compound, and V8 Peptides does not sell it
Eloralintide is an investigational compound. Based on the sources reviewed, it is not approved by any regulator, and the clinical studies above are run by its developer under their own protocols. V8 Peptides does not sell eloralintide. If you see it offered as a laboratory material, the rest of this article explains why a careful buyer would want strong evidence of identity first.
General buyer guidance for brand-new compound names
A newly discussed compound is where mislabelled or substituted material is most likely to appear. Demand outruns the supply of well-characterised reference material, and a vial name is just text on a label. These are general checks, not statements about any particular seller.
- Identity must be confirmed analytically. A purity percentage by itself says how clean a peak is, not what the peak is. Ask what method confirmed the molecule and what it was compared with. Understanding HPLC purity explains the limits of a purity figure.
- A certificate should name the compound and the lot. The compound name, lot number and test date should match the vial in your hands. A generic report with no lot is not evidence about your material. Our guide on how to read a COA walks through each field, and the COA page shows what a certificate looks like.
- A new name with no published reference standard is a caution sign. If the sequence has not been published, there may be nothing authoritative to compare against, so an identity claim cannot be checked properly.
- Watch for substitution. Because several amylin-pathway peptides exist, a seller could label one as another. See red flags when buying research peptides for the general warning signs.
If your interest is the better-documented relative, see where to buy cagrilintide, the cagrilintide purity testing guide, or the cagrilintide product page.
Common misunderstandings
“Eloralintide is just a new name for cagrilintide.” The literature describes different developers and different receptor profiles, so they are not the same compound.
“Published trials mean it is approved.” Publication reports what was studied. It is not a regulatory decision.
“A nickname is enough to search with.” Use the full name and the LY3841136 code so you land on primary records.
Frequently asked questions
What is eloralintide?
An investigational, once-weekly, selective amylin receptor agonist peptide being developed by Eli Lilly and Company under the code LY3841136. It is not an approved product.
Who makes eloralintide?
Eli Lilly and Company is the developer and the registered sponsor of its clinical trials.
What is LY3841136?
It is the development code for eloralintide. Trial records list the two names for the same compound.
Is eloralintide the same as cagrilintide?
No. Cagrilintide is described in the literature as a non-selective amylin receptor agonist that also acts at the calcitonin receptor, and its sponsor is Novo Nordisk. Eloralintide is described as selective and comes from Lilly.
What does selective amylin receptor agonist mean?
It means the compound was characterised as favouring certain amylin receptor subtypes over the calcitonin receptor in the assays reported by its developer.
What is the sequence or molecular weight of eloralintide?
This is not publicly confirmed in the sources reviewed for this article, so none is given here. Be cautious about any source that states one without a citation.
What stage of development is eloralintide at?
Phase 2 results have been published, and Phase 3 studies are registered on ClinicalTrials.gov. Registry status can change, so check the records directly.
Does V8 Peptides sell eloralintide?
No. V8 Peptides does not sell eloralintide.
What does 'elora' mean?
It is informal shorthand for eloralintide, not an official name. Use the full name or the code LY3841136 when searching records.
How can I tell if a new-name compound is mislabelled?
Look for a certificate that names the compound and the lot, an analytical identity result tied to a reference, and a published reference standard. If no reference exists yet, regard identity claims with caution.
Research Use Only: V8 Peptides products are sold for laboratory research use only. They are not drugs, foods or cosmetics and are not intended for human or animal consumption. This article is research education and is not a product listing.
References
- Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 2025 Dec. PMID: 41109426.
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025 Dec 6. PMID: 41207310.
- Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism. 2026 Apr. PMID: 41559929.
- Alhazmi A, le Roux CW. Amylin analogs: the next major class of weight loss therapy: a review of experimental data and early-phase clinical trials. Diabetes, Obesity and Metabolism. 2026 Sep. PMID: 42452898.
- Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026 Mar. PMID: 41747885.
- ClinicalTrials.gov. NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight. https://clinicaltrials.gov/study/NCT06230523 ; also registry search for eloralintide and LY3841136 (Phase 3 and other records cited in text): https://clinicaltrials.gov/search?term=eloralintide
- Eli Lilly and Company. Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. Press release, 6 Nov 2025. https://lilly.mediaroom.com/2025-11-06-Lillys-selective-amylin-agonist,-eloralintide,-demonstrated-meaningful-weight-loss-and-favorable-tolerability-in-a-Phase-2-study-of-adults-with-obesity-or-overweight